# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `full27_study-forensics-032_Claude_Opus_245a96`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:07:14.766608+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Opus
**Winner:** Claude Opus — **37.2/100** (margin: 0.0)
**Failure modes:** confidence_mismatch, decorative_uncertainty, missed_key_insight, unsupported_conclusion, wrong_answer
**Forensic flags:** 2
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Opus | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 2.7/6 | 4.5/6 | 2.4/8 | 8.0/8 | 0.0/10 | 10.0/10 | **37.2/100** |

## Study Forensics Audit

### Claude Opus

**Classification:** `mechanism_vs_evidence` [x] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** mechanism_not_demonstrated

## Reasoning Integrity Audit

### Claude Opus
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 6

## Mechanism Analysis

### Claude Opus
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Opus
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "mechanism_vs_evidence"


## Forensic Flags

### Claude Opus

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "mechanism_vs_evidence"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "mechanism_vs_evidence"


## Evidence Map

### Claude Opus

**Correctness:** 0.0/30
  - (+) `final_answer`: "mechanism_vs_evidence"
    _Agent's answer for correctness check_
  - Note: No match (got: mechanism_vs_evidence)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "mechanism_vs_evidence"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 6
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[5]`: "Company seeks accelerated approval based on surrogate endpoint without clinical outcome data"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 0/6 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "No cardiovascular events were tracked means no heart attacks, strokes, or deaths were measured"
    _Most substantive assumption_
  - Note: 4/4 substantive assumptions

**Uncertainty Handling:** 2.7/6
  - (+) `uncertainties[0]`: "Whether LDL reduction in this specific population (familial hypercholesterolaemia on statins) has established surrogacy "
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.95"
    _Stated confidence level_
  - (-) `uncertainties[1]`: "The exact wording of company statements beyond what's summarized"
    _Listed but never addressed in reasoning_
  - Note: 2 uncertainties (2 substantive)
  - Note: 1 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[0]`: "Could be overclaim if focusing on the 'major breakthrough' language"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 genuinely diverse alternatives

**Self Monitoring Quality:** 2.4/8
  - (+) `self_check[1]`: "Confirmed the company is making clinical benefit claims, not just reporting biomarker changes"
    _Most substantive self-verification step_
  - (-) `self_check[2]`: "The lack of hedging language from executives strengthens the classification"
    _Fluff self-check_
  - Note: 4 self-check items
  - Note: Self-check quality: 0 deep, 2 arithmetic, 2 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.72, 273 words

**Insight Depth:** 8.0/8
  - (+) `(output text)`: "accelerated approval based on surrogate endpoint without clinical outcome data"
    _Insight 'surrogate endpoint' matched (exact)_
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Opus

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'overclaim'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'overclaim', detected 'mechanism_vs_evidence'
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "mechanism_vs_evidence"
  - _Impacts: support_strength_
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**MINOR:**
- **Confidence Mismatch** `[MEDIUM CONFIDENCE]`: Very high confidence (0.95) on medium task
  - `confidence`: "confidence: 0.95"
  - _Impacts: uncertainty_handling_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'The exact wording of company statements beyond what's summar...' is listed but not addressed
  - `uncertainties[1]`: "The exact wording of company statements beyond what's summarized"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Opus

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (2/14 content words)
  - `key_claims[0]`: "Clear mechanism vs evidence issue: biomarker evidence (LDL reduction) used to claim clinical benefit"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/10 content words)
  - `key_claims[1]`: "Company making therapeutic efficacy claims without measuring actual cardiovascular events"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/10 content words)
  - `key_claims[2]`: "Four-year gap before outcomes data available highlights the premature nature of efficacy claims"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 2 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[1]`: "The exact wording of company statements beyond what's summarized"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "Could be overclaim if focusing on the 'major breakthrough' language"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "Could be solid if the text had limited claims to just LDL reduction"


## Agent Profiles

### Claude Opus (claude-opus-4-20250514)
**Parse OK:** True | **Latency:** 18626ms

**Final Answer:** mechanism_vs_evidence

**Confidence:** 0.95

**Assumptions:**
- The Phase 2 trial was properly conducted and the 65% LDL reduction is accurate
- The trial only measured biomarkers (LDL cholesterol) and safety, not clinical outcomes
- No cardiovascular events were tracked means no heart attacks, strokes, or deaths were measured
- The company is seeking approval based solely on the biomarker data

**Reasoning Steps:**
1. Identified that this is a Phase 2 trial measuring only LDL cholesterol reduction (biomarker)
2. Noted the company claims this will 'transform outcomes for patients at high risk of heart attack and stroke'
3. Recognized the gap: evidence shows LDL reduction, but conclusions claim cardiovascular event reduction
4. Confirmed no cardiovascular events were tracked in the trial
5. The bridge from 'LDL reduction' to 'preventing heart attacks and strokes' is assumed but not demonstrated
6. Company seeks accelerated approval based on surrogate endpoint without clinical outcome data

**Key Claims:**
- Clear mechanism vs evidence issue: biomarker evidence (LDL reduction) used to claim clinical benefits (preventing heart attacks/strokes)
- Company making therapeutic efficacy claims without measuring actual cardiovascular events
- Four-year gap before outcomes data available highlights the premature nature of efficacy claims

**Alternative Hypotheses:**
- Could be overclaim if focusing on the 'major breakthrough' language
- Could be solid if the text had limited claims to just LDL reduction

**Uncertainties:**
- Whether LDL reduction in this specific population (familial hypercholesterolaemia on statins) has established surrogacy for cardiovascular outcomes
- The exact wording of company statements beyond what's summarized

**Self-Verification:**
- Verified this is not overclaim - the issue is specifically about evidence tier mismatch
- Confirmed the company is making clinical benefit claims, not just reporting biomarker changes
- The lack of hedging language from executives strengthens the classification
- This is a textbook case of surrogate endpoint being treated as clinical endpoint

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 2.7/6 `####......`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 2.4/8 `###.......`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Opus** scored **37.2/100**.

**Best per dimension:**
- Correctness: Claude Opus (0.0/30)
- Support Strength: Claude Opus (0.0/8)
- Structural Reasoning: Claude Opus (4.8/8)
- Assumption Discipline: Claude Opus (4.8/6)
- Uncertainty Handling: Claude Opus (2.7/6)
- Alternative Hypothesis Quality: Claude Opus (4.5/6)
- Self Monitoring Quality: Claude Opus (2.4/8)
- Insight Depth: Claude Opus (8.0/8)
- Mechanism Quality: Claude Opus (0.0/10)
- Communication Efficiency: Claude Opus (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Opus | 18.6s | 37.2/100 | 2.0 |

Failure modes observed: confidence_mismatch, decorative_uncertainty, missed_key_insight, unsupported_conclusion, wrong_answer.
